SCHEMBL14927441

SCHEMBL14927441

CCCn1c(=O)n(C(C)c2ccccc2)c(=O)c2cc(C)ccc21

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 2/20 0.49
▸ RORA P35398 2/20 0.49
▸ RORC P51449 2/20 0.49
▸ RORB Q92753 2/20 0.49
▸ SLC6A2 P23975 4/20 0.45
▸ SLC6A4 P31645 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPD P32754 1/20 0.40
▸ PARG Q86W56 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ADORA2B P29275 2/20 0.39
▸ ADORA1 P30542 2/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14927458 0.89 RORA (0.43) PGRRORARORCRORBSLC6A2
SCHEMBL10085014 0.83 PARG (0.48) PGRRORARORCRORBSLC6A2
SCHEMBL14927388 0.80 TP53 (0.56) PGRRORARORCRORBTP53
SCHEMBL10084697 0.79 PGR (0.57) PGRRORARORCRORBKDM4E
SCHEMBL16676871 0.76 TSHR (0.57) PGRKDM4EGAATP53KMT2A
SCHEMBL14927465 0.75 PGR (0.48) PGRRORARORCRORBKDM4E
SCHEMBL14927365 0.74 PGR (0.50) PGRRORARORCRORBPARG
SCHEMBL14927475 0.74 RORA (0.53) PGRRORARORCRORBHPD
SCHEMBL10085035 0.73 KDM4E (0.48) PGRRORARORCRORBKDM4E
SCHEMBL10084495 0.72 KDM4E (0.44) KDM4EPARGTP53LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH PGR 844/4885RORA 1071/4885RORC 1361/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 PGR 1453/4885RORA 2447/4885RORC 2557/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH PGR 844/4885RORA 1071/4885RORC 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback